Ronald Levy

Dr. Ronald Levy is a Professor of Medicine, Director of the Lymphoma Program, and Former Chief of the Division of Oncology at Stanford University. He obtained his bachelor's degree in biochemistry from Harvard University in 1963 and his medical degree from Stanford University in 1968. He is an elected member of the National Academy of Sciences and the Institute of Medicine.

Dr. Levy's research has focused for more than 20 years on monoclonal antibodies to B cells. He was the first to successfully treat human lymphoma with a monoclonal antibody and went on to make important contributions to the development of rituximab (Rituxan®), for the treatment of patients with resistant low-grade lymphomas. He is currently conducting clinical trials of a lymphoma vaccine. His research concentrates on the study of malignant lymphoma, using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. Dr. Levy is using lymphocyte receptors as targets for new therapies for lymphoma. Dr. Levy has published over 270 articles in the fields of oncology and immunology.